Tuberactinomycins の実験的抗結核性について

概要

論文の詳細を見る
Tuberactinomycin, TUM, is a collective name for a group of peptide antibiotics among which TUMs A, B, N and O may be distinguished. In 1968 Nagata et al. reported the antituberculous antibiotic tuberactin produced from a strain, B-386, of Streptomyces griseoverticillatus var. tuberacticus, which was later renamed TUM and finally found to be a mixture of two components A and B; the latter identified as viomycin. A mutant of the strain, designated N-130, produced TUMs N and 0.<BR>The present paper describes an attempt designed to compare the in vitro and in vivo activities of these components and also reports cross-resistance studies in vitro.<BR>In vitro observations: The results are recorded in Tables 1 and 2. It may be noted that each of the TUMs inhibited the growth of the H37Rv drug-susceptible strain in a concentration of 4 or 8mcg per ml in Kirchners semi-liquid medium with 10per cent horse serum, and of 25mcg per ml in Ogawas egg medium. Cross-resistance studies were performed utilizing 22 drug-resistant H37Rv strains. The strains resistant to SM, KM, PAS, INH, CS, EB, ETH, and RFP were all sensitive to the TUMs (TUM-A, Me-TUM-A, and TUM-N), whereas the VM and CPM-resistant strains were resistant to the TUMs. On the: other hand, the strains resistant to TUMs were all susceptible to SM, PAS, INH, CS, EB, ETH, and RFP, but not to VM and CPM. The slightly TUM-resistant strains (nos. 22 and 24 in Table 2-b) were sensitive to KM, whereas the highly TUM-resistant strains (nos. 21 and 23) were resistant to KM. In brief, among the strains resistant to TUMs, VM, and CPM complete reciprocal cross-resistance was observed, while incomplete non-reciprocal. cross-resistance was found between the strains resistant to TUMs and KM.
日本結核病学会の論文

Tuberactinomycins の実験的抗結核性について

スポンサーリンク

概要

著者

関連論文

スポンサーリンク